These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34482189)

  • 21. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.
    Sorah JD; Rose TL; Radhakrishna R; Derebail VK; Milowsky MI
    J Immunother; 2021 Apr; 44(3):127-131. PubMed ID: 32925564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies.
    Panich J; Irwin C; Bissonette A; Elkhidir S; Lodhi F; Folz C; Lee J; Pulipati S; Fatima Z; Gopinath P; Blonsky R; Abboud Leon C; Kattamanchi S
    J Oncol Pharm Pract; 2024 Mar; 30(2):286-294. PubMed ID: 37125423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 1-year decline in estimated glomerular filtration rate (eGFR) after radical nephrectomy in patients with renal masses and matched living kidney donors is the same.
    Hew MN; Opondo D; Cordeiro ER; van Donselaar-van der Pant KA; Bemelman FJ; Idu MM; de la Rosette JJ; Laguna MP
    BJU Int; 2014 May; 113(5b):E49-55. PubMed ID: 24053637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
    Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
    Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma.
    Singla N; Hutchinson R; Menegaz C; Haddad AQ; Jiang L; Sagalowsky AI; Cadeddu JA; Lotan Y; Margulis V
    Urology; 2016 Oct; 96():44-53. PubMed ID: 27443467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
    Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
    Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
    Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
    Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy.
    Martini A; Cumarasamy S; Beksac AT; Abaza R; Eun DD; Bhandari A; Hemal AK; Porter JR; Badani KK
    Eur Urol; 2018 Dec; 74(6):833-839. PubMed ID: 30224195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
    Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
    Front Immunol; 2022; 13():898811. PubMed ID: 35967405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S; Joshi SS; Narayan VM; Kissick H; Ogan K; Master VA; Carthon BC; Kucuk O; Bilen MA
    Oncologist; 2023 Dec; 28(12):1072-1078. PubMed ID: 37285524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute kidney injury following coronary angiography: a nationwide study of incidence, risk factors and long-term outcomes.
    Helgason D; Long TE; Helgadottir S; Palsson R; Sigurdsson GH; Gudbjartsson T; Indridason OS; Gudmundsdottir IJ; Sigurdsson MI
    J Nephrol; 2018 Oct; 31(5):721-730. PubMed ID: 30187381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Kato M; Uchida J
    Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.